Clinical Trial

A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC

Study acronym: eVOLVE-RCC02
Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a Phase Ib/III, randomized, multicenter, global study evaluating the efficacy and safety of volrustomig in combination with casdatifan for the first-line (1L) treatment of participants with advanced clear cell renal cell carcinoma (ccRCC). The Phase III part of the study will no longer be conducted.
Protocol Amendment History 7 changes
critical Phase changed: Phase 3 -> Phase 1 2026-08-04
critical Primary endpoint(s) modified 2026-08-04
notable Enrollment reduced: 1116 -> 9 participants 2026-08-04
minor Trial arms changed: 5 -> 2 2026-08-04
notable Trial sites reduced: 32 -> 3 locations 2026-08-04
notable Primary completion moved earlier: 2030-02-21 -> 2027-01-29 2026-08-04
minor Completion moved earlier: 2032-07-29 -> 2027-01-29 2026-08-04
Trial Details
NCT Number NCT07000149
Lead Sponsor AstraZeneca
Collaborators: Arcus Biosciences, Inc.
Conditions Advanced Clear Cell Renal Cell Carcinoma
Enrollment 9 participants
Start Date 2025-07-28
Primary Completion 2027-01-29 (estimated)
Study Completion 2027-01-29 (estimated)
Updated on ClinicalTrials.gov 2026-08-03